CANCERCare
A PROGRAM OF EASTERN HEALTH
Cancer Care Program

Doctor's Order Sheet

daratumumab-hyaluronidase 1800 mg - lenalidomide 25 mg - dexamethasone 40 mg

Regimen: Cycles 3-6 (Part I)

ARIA Protocol Name: Dara SC Len Dex

Adult Chemotherapy - Hematology Oncology

Multiple Myeloma

Name:

HCN:

Date of Birth:

CC5770 0387 08 2023

Allergies: ☐ **No Known**

Date: DD/MONTH/YYYY ________ Planned Administration Date: DD/MONTH/YYYY ________

Cycle_______ of _______ **Cycle Duration: 28 days** Date of previous cycle: DD/MONTH/YYYY ________

MAY PROCEED WITH DOSES AS WRITTEN IF:

- ANC **greater than or equal to** 1 X 10^9/L and platelets **greater than or equal to** 50 X 10^9/L, otherwise notify Hematologist.
- LFTs and Bilirubin assessed.
- Creatinine clearance assessed.

PREMEDICATIONS (FOR HOSPITAL PHARMACY):

☐ **60 minutes prior to daratumumab-hyaluronidase: acetaminophen 650 mg PO** on day 1 and 15

☐ **60 minutes prior to daratumumab-hyaluronidase: diphenhydrAMINE 50 mg PO** on day 1 and 15

☐ Other: ____

HYDRATION/SUPPORTIVE CARE (FOR COMMUNITY PHARMACY):

☐ **acetylsalicylic acid 81 mg PO** once daily

☐**acyclovir 800 mg PO** once daily until 4 weeks post completion of daratumumab treatment

☐ **metoclopramide 10-20 mg PO** every 4 hours as needed

☐ Other: ____

PLEASE REFER TO CHEMOTHERAPY LETTER WHEN ORDERING SUPPORTIVE MEDICATIONS FOR THIS PATIENT

Authorized Prescriber: ____________________ Date: DD/MONTH/YYYY ______Time: __________

Authorized Prescriber's Signature: ______________________________ ID #: ____________________

Nurse's Name: ____________________ Date: DD/MONTH/YYYY ____________ Time: __________

Nurse's Signature: ______________________________

THIS IS A CONTROLLED DOCUMENT. PLEASE ENSURE THAT YOU ARE READING THE MOST RECENT VERSION.

Cancer Care Program

Doctor's Order Sheet

daratumumab-hylauronidase 1800 mg - lenalidomide 25 mg - dexamethasone 40 mg Regimen: Cycles 3-6 (Part II)

ARIA Protocol Name: Dara SC Len Dex

Adult Chemotherapy - Hematology Oncology

Multiple Myeloma

CC5770 0387 08 2023

Name:

HCN:

Date of Birth:

Weight: __________kg Height:__________________cm Body Surface Area (BSA) = __________________

CHEMOTHERAPY (FOR HOSPITAL PHARMACY):

☐ **daratumumab-hyaluronidase 1800 mg**

SC on day 1 and 15

Administer over 3 to 5 minutes into abdomen

First injection: Observe patient for 4 hours after daratumumab-hyaluronidase SC injection

Subsequent injections: If no reaction in previous injection, observe patient for 15 to 20 minutes after daratumumab-hyaluronidase SC injection

CHEMOTHERAPY (FOR COMMUNITY PHARMACY):

☐ **dexamethasone 40 mg PO** on day 1, 8, 15 and 22 (60 minutes pre daratumumab-hyaluronidase on day 1 and 15)

☐ **lenalidomide 25 mg PO** once daily on days 1 to 21 (ensure patient enrolled in managed access program)

- ☐ Dose modification: **lenalidomide 20 mg PO** once daily on days 1 to 21
- ☐ Dose modification: **lenalidomide 15 mg PO** once daily on days 1 to 21
- ☐ Dose modification: **lenalidomide 10 mg PO** once daily on days 1 to 21
- ☐ Dose modification: **lenalidomide 15 mg PO** every other day on days 1 to 21
- ☐ Dose modification: **lenalidomide 5 mg PO** once daily on days 1 to 21
- ☐ Dose modification: **lenalidomide 2.5 mg PO** once daily on days 1 to 21

This prescription is NOT eligible for pharmacist prescribing by dispensing pharmacist

PLEASE REFER TO CHEMOTHERAPY LETTER WHEN ORDERING SUPPORTIVE MEDICATIONS FOR THIS PATIENT

Authorized Prescriber: __________________________ Date: DD/MONTH/YYYY________________Time: _________

Authorized Prescriber's Signature: __________________________________ ID #: _____________________________

Nurse's Name: ____________________________ Date: DD/MONTH/YYYY__________________ Time: _________

Nurse's Signature: ____

THIS IS A CONTROLLED DOCUMENT. PLEASE ENSURE THAT YOU ARE READING THE MOST RECENT VERSION.